Pharma

10 stories about Pharma
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
default image

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
default image

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
תרופות  טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
מפעל חברת טבע הר חוצבים ירושלים

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist
Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts